Tumor heterogeneity in antigen expression can affect the efficacy of ADCs, and this has been observed in the KRISTINE trial, a Phase II study for Trastuzumab emtansine, a HER2-targeted ADC, plus pertuzumab in the neoadjuvant setting for patients with breast cancer. The gene discussed is ERBB2; the disease is neoplasm.